{"page":{"totalFilteredElements":75},"studies":[{"active":true,"description":"A randomized, double-blind study to compare efficacy, pharmacokinetics, safety, and immunogenicity between ABP 234 and Keytruda (Pembrolizumab) in subjects with advanced or metastatic non-squamous non-small cell lung cancer","eudractNumber":"2023-508336-57","id":10260,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06311721","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-09-30T08:09:58+02:00","shortTitle":"20210033","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Preoperative FOLFOX versus postoperativ risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized Phase III Trial of the German Rectal Cancer Study Group.","eudractNumber":"2018-001356-35","id":5571,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04495088","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-04-16T10:14:02+02:00","shortTitle":"ACO/ARO/AIO-18.2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Adjuvant Dynamic marker - Adjusted Personalized Therapy \ncomparing adjuvant Elacestrant with standard endocrine \ntreatment in genomically and/or clinically high-risk ER+/HER2- \nearly breast cancer","eudractNumber":"2025-522484-15-00","id":12036,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT07242352","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-06-23T11:08:21+02:00","shortTitle":"ADAPTela","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A randomized phase 3, double-blind, placebo-controlled study of elacestrant in patients with estrogen receptor - positive/ human groth factor receptor 2 negative, ESR1-mutaed, advanced breast cancer progressing to endocrine therapy and CDK 4/6 inhibitors","eudractNumber":"2024-512926-27-00","id":12013,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"ESR1 (Estrogen Receptor 1 Gen)","id":"mt_207"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06382948","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":null,"shortTitle":"ADELA","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Niraparib vs. Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicenter randomised phase III trial)","eudractNumber":"2024-516066-11-00","id":8116,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05009082","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-10-21T11:30:38+02:00","shortTitle":"AGO-Ovar 28","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"Randomisierte Studie zur Evaluation der Wirksamkeit einer Cetuximab-Reexposition bei Patienten mit metastasiertem kolorektalem Karzinom (RAS Wildtyp), welche auf eine Erstlinien-Behandlung mit FOLFIRI plus Cetuximab ein Ansprechen zeigten","eudractNumber":"2014-003787-21","id":2884,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"NRAS","id":"mt_6"},{"name":"KRAS","id":"mt_7"}],"nctNumber":"NCT02934529","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2017-02-17T12:22:59+01:00","shortTitle":"AIO-KRK-0114/ FIRE-4","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Prospektive, randomisierte, offene, multizentrische Phase III Studie zur Untersuchung der Wirksamkeit einer Therapie in Patienten mit metastasiertem kolorektalen Karzinom, nach erfolgter Resektion oder Ablation<div><b>DRKS00027138</b><br /></div>","eudractNumber":"2020-006144-18","id":7450,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-11-17T14:29:54+01:00","shortTitle":"AIO-KRK-0418 / FIRE-9 - PORT","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study \nEvaluating The Safety And Efficacy Of Efruxifermin (EFX) In Subjects with Non-Cirrhotic Non-alcoholic Steatohepatitis (NASH) \nAnd Fibrosis","eudractNumber":"2023-505141-48-00","id":9598,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06215716","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-03-28T08:46:05+01:00","shortTitle":"AK-US-001-0105","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"International cooperative study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of vinblastine<br />","eudractNumber":"2017-002935-40","id":4034,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped2","name":"Lymphome"}],"mutations":[{"name":"ALK","id":"mt_11"}],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-04-14T09:44:08+02:00","shortTitle":"ALCL-VBL","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator&#8217;s Choice in Participants with Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer</div>","eudractNumber":"2025-520555-89","id":11331,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07213674","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-15T10:26:05+01:00","shortTitle":"AMG 509 20230239","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]}]}